NASDAQ:STAA - Nasdaq - US8523123052 - Common Stock - Currency: USD
NASDAQ:STAA (5/13/2025, 3:26:38 PM)
19.235
-1.04 (-5.11%)
The current stock price of STAA is 19.235 USD. In the past month the price increased by 20.73%. In the past year, price decreased by -52.53%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ALC | ALCON INC | 30.78 | 46.90B | ||
COO | COOPER COS INC/THE | 21.83 | 16.46B | ||
ALGN | ALIGN TECHNOLOGY INC | 20.45 | 13.97B | ||
SOLV | SOLVENTUM CORP | 12.43 | 12.80B | ||
MMSI | MERIT MEDICAL SYSTEMS INC | 27.52 | 5.81B | ||
LNTH | LANTHEUS HOLDINGS INC | 12.09 | 5.48B | ||
BLCO | BAUSCH + LOMB CORP | 24.38 | 4.13B | ||
ICUI | ICU MEDICAL INC | 20.76 | 3.57B | ||
HAE | HAEMONETICS CORP/MASS | 15.16 | 3.48B | ||
XRAY | DENTSPLY SIRONA INC | 9.97 | 3.34B | ||
UFPT | UFP TECHNOLOGIES INC | 29.97 | 1.94B | ||
NEOG | NEOGEN CORP | 17.29 | 1.43B |
STAAR Surgical Co. engages in the design, development, manufacture, and sale of ophthalmic surgical products. The company is headquartered in Monrovia California, California and currently employs 1,157 full-time employees. The firm markets and sells its ICLs for refractive surgery to treat myopia (nearsightedness) as its EVO family of lenses. Its EVO family of lenses includes its EVO ICL, EVO+ ICL, and EVO Visian ICL. The firm's newest offering, EVO Viva, has an extended depth of focus (EDoF) optic, which is designed to treat myopia with presbyopia (age-related loss of ability to focus). The company also market and sell an ICL lens to treat hyperopia (farsightedness), called Visian ICL. The company makes its ICL product offerings available in multiple models, powers and lengths, including some with toric ICL (TICL) versions to correct for astigmatism (blurred vision). The Company’s principal products are ICLs used in refractive surgery, including its EVO family of lenses.
STAAR SURGICAL CO
1911 Walker Ave
Monrovia California CALIFORNIA 92630 US
CEO: Caren Mason
Employees: 1157
Phone: 16263037902
The current stock price of STAA is 19.235 USD. The price decreased by -5.11% in the last trading session.
The exchange symbol of STAAR SURGICAL CO is STAA and it is listed on the Nasdaq exchange.
STAA stock is listed on the Nasdaq exchange.
20 analysts have analysed STAA and the average price target is 22.04 USD. This implies a price increase of 14.56% is expected in the next year compared to the current price of 19.235. Check the STAAR SURGICAL CO stock analysts ratings, price target forecast and up-and down grades for more detailed information.
STAAR SURGICAL CO (STAA) has a market capitalization of 952.71M USD. This makes STAA a Small Cap stock.
STAAR SURGICAL CO (STAA) currently has 1157 employees.
STAAR SURGICAL CO (STAA) has a support level at 16.41 and a resistance level at 40.26. Check the full technical report for a detailed analysis of STAA support and resistance levels.
The Revenue of STAAR SURGICAL CO (STAA) is expected to decline by -24.28% in the next year. Check the estimates tab for more information on the STAA EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
STAA does not pay a dividend.
STAAR SURGICAL CO (STAA) will report earnings on 2025-08-05, after the market close.
STAAR SURGICAL CO (STAA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.28).
The outstanding short interest for STAAR SURGICAL CO (STAA) is 12.61% of its float. Check the ownership tab for more information on the STAA short interest.
ChartMill assigns a technical rating of 4 / 10 to STAA. When comparing the yearly performance of all stocks, STAA is a bad performer in the overall market: 71.2% of all stocks are doing better.
ChartMill assigns a fundamental rating of 4 / 10 to STAA. While STAA has a great health rating, its profitability is only average at the moment.
Over the last trailing twelve months STAA reported a non-GAAP Earnings per Share(EPS) of -0.28. The EPS decreased by -143.75% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -3.97% | ||
ROE | -5.09% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 71% to STAA. The Buy consensus is the average rating of analysts ratings from 20 analysts.
For the next year, analysts expect an EPS growth of -373.06% and a revenue growth -24.28% for STAA